We identified a unique antibody gene mutation pattern (i.e. "signature") in cerebrospinal fluid (CSF) B cells from multiple sclerosis (MS) patients not present in control populations. Prevalence of the signature in CSF B cells of patients at risk to develop MS predicted conversion to MS with 91% accuracy in a small cohort of clinically isolated syndrome patients. If confirmed, signature prevalence would be a novel genetic diagnostic tool candidate for patients with early demyelinating disease of the central nervous system.
Introduction
B cells have historically been implicated in the pathogenesis of multiple sclerosis (MS) since elevated central nervous system (CNS) gamma immunoglobulins were first described in MS patients in the 1940s (Kabat et al., 1948) . Additional evidence of B cell involvement in MS pathogenesis is extensive (reviewed in (Antel and Bar-Or, 2006; Duddy and Bar-Or, 2006; Franciotta et al., 2008; Frohman et al., 2006; Martin Mdel and Monson, 2007; McLaughlin and Wucherpfennig, 2008; Owens et al., 2006) ) and has been recently substantiated by the efficacy of rituximab (Rituxan), a B cell depleting antibody, in a cohort of patients with relapsing remitting MS (RRMS) (Hauser et al., 2008) . Furthermore, Rituxan and intravenous immunoglobulin, drugs that solely affect B cells or their antibody products, have been reported to decrease severity of disease in MS patients refractory to benefit with corticosteroids, interferon-beta, and mitoxantrone (Achiron, 2008; Leussink et al., 2008; Stuve et al., 2005; Tselis et al., 2008) .
Several groups investigating the role of B cells in MS have hypothesized that the distribution of genes used to generate antibodies in B cells from the cerebrospinal fluid (CSF) and brain lesions of MS patients are different from expected distributions. Indeed, the distributions are different in some cases, particularly with regard to a family of variable heavy chains (VH4), which are significantly increased in frequency compared to expected distributions (Baranzini et al., 1999; Colombo et al., 2000; Harp et al., 2007; Monson et al., 2005; Owens et al., 1998 Owens et al., , 2003 Owens et al., , 2007 Qin et al., 1998; Ritchie et al., 2004) . Additionally, MS CSF B cells show extensive clonal expansion and high mutational frequencies in the CSF B cell pool from this population of patients (Baranzini et al., 1999; Colombo et al., 2000; Monson et al., 2005; Owens et al., 2003; Qin et al., 1998; Ritchie et al., 2004) , and the antibodies these cells produce bind to neuroantigens (Kolln et al., 2006; Lambracht-Washington et al., 2007) . In contrast, VH4 expressing B cells in the periphery of healthy donors (Brezinschek et al., 1995 (Brezinschek et al., , 1997 , MS patients (Owens et al., 2007) , and VH4 expressing B cells in the CSF of patients with other neurological diseases (OND) are present at expected frequencies (Table 1 and (Harp et al., 2007) ).
Since antibody gene mutation patterns are influenced by antigen driven selection, we hypothesized that VH4 expressing CSF-derived B
